Compare Hilton Hotels Corporation Common Stock (HLT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Zoetis Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $327.15 (market cap $72.76B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Zoetis Inc for 70 Days on average.
| HLT | ZTS | |
|---|---|---|
Market Cap | $72.76B | $30.20B |
Volume | 1,148,634 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $147.53 |
52-Week Low | $256.96 | $69.09 |
Typical Hold Time | 138 Days | 70 Days |
Enterprise Value | $85.78B | $37.76B |
Dividend Yield | 0.19% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $327.48, up 2.18% today, reflecting strong momentum near its recent highs. The stock shows a bullish technical setup with consistent earnings beats in recent quarters and solid revenue growth, with 2025 revenue reaching $12.04 billion. Analyst sentiment is positive, with a consensus price target of $348.11 and no sell ratings among 49 analysts. Recent news highlights institutional buying and the upcoming Q3 2026 earnings report on October 27, 2026.
The outlook for HLT remains favorable, driven by robust travel demand, global portfolio expansion, and strong operational cash flow. Key risks include high debt levels, with a debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles. Upside potential hinges on continued execution and market share gains in high-growth regions like Asia, as noted in recent company reports.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
